SCHEMBL5451470

SCHEMBL5451470

CCOc1ccc(F)cc1NC(=O)Nc1ccc(N2CCN(C(=O)Nc3ncc(Cl)cc3Cl)CC2)cc1

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 10/20 0.49
ALK Q9UM73 1/20 0.47
LMNA P02545 4/20 0.47
SMN1; SMN2 Q16637 2/20 0.47
MAPK1 P28482 2/20 0.47
HPGD P15428 2/20 0.47
ALDH1A1 P00352 4/20 0.46
MEN1 O00255 2/20 0.45
KMT2A Q03164 2/20 0.45
HTT P42858 1/20 0.45
NPSR1 Q6W5P4 1/20 0.45
PANK3 Q9H999 1/20 0.44
NPC1 O15118 1/20 0.44
L3MBTL1 Q9Y468 2/20 0.43
P2RY12 Q9H244 2/20 0.43
POLB P06746 1/20 0.43
HTR1A P08908 1/20 0.43
HTR1D P28221 1/20 0.43
HTR1B P28222 1/20 0.43
HTR2A P28223 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5465503 0.93 MAPT (0.53) MAPTALKLMNASMN1; SMN2MAPK1
SCHEMBL5460920 0.91 KMT2A (0.56) MAPTALKLMNASMN1; SMN2MAPK1
SCHEMBL5457985 0.84 NPC1 (0.50) MAPTSMN1; SMN2ALDH1A1MEN1KMT2A
SCHEMBL5460431 0.83 MAPT (0.54) MAPTLMNASMN1; SMN2MAPK1ALDH1A1
SCHEMBL5462591 0.82 MAPT (0.49) MAPTLMNASMN1; SMN2ALDH1A1MEN1
SCHEMBL5462041 0.81 TRPV1 (0.48) MAPTLMNASMN1; SMN2HPGDALDH1A1
SCHEMBL5460880 0.81 MAPT (0.49) MAPTLMNASMN1; SMN2ALDH1A1MEN1
SCHEMBL5459445 0.81 RBP4 (0.54) MAPTLMNASMN1; SMN2MAPK1HPGD
SCHEMBL5464810 0.80 KMT2A (0.54) MAPTLMNASMN1; SMN2ALDH1A1MEN1
SCHEMBL5463477 0.79 TRPV1 (0.53) MAPTLMNASMN1; SMN2MAPK1HPGD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20070249620-A1 Urea Derivative SANKYO COMPANY, LIMITED (JP) 2007-10-25 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070249620-A1 Urea Derivative UGP2, SLC14A1, DGAT1 MAPT 758/4885ALK 3756/4885LMNA 3721/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.